At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Apr 30, 2026 at 20:00 ET
Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligand's strong Q1 earnings (royalty revenue +56% YoY) and the reaffirmation of raised 2026 guidance tied to the pending XOMA acquisition. The sales are small relative to the $4.4B market cap (0.0035%) and likely reflect routine portfolio rebalancing or tax planning, not a bearish signal on fundamentals.
- Two insiders sold a total of 680 shares for $155K on May 1, 2026.
- Sales represent ~0.0035% of Ligand's $4.4B market cap, trivial in size.
- Director Kozarich also exercised and sold shares on May 12-13, 2026, in a separate cluster ($455K total).
- Q1 2026 earnings showed royalty revenue up 56% YoY to $43M; adjusted EPS of $1.63 beat prior year's $1.33.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access